Comparison of No-reflow Phenomenon After Percutaneous Coronary Intervention for Acute Myocardial Infarction Between Smokers and Nonsmokers

Overview

Journal J Res Med Sci

Specialty General Medicine

Date 2015 Feb 7

PMID 25657753

Citations 4

Authors

Hassan Shemirani

Faezeh Dehghani Tafti

Afshin Amirpour

Affiliations

Soon will be listed here.

Abstract

Background: No-reflow phenomenon after percutaneous coronary intervention (PCI) in patients with acute ST-segment-elevation myocardial infarction (STEMI) is relatively common and has therapeutic and prognostic implications. Cigarette smoking is known as deleterious in patients with coronary artery disease (CAD), but the effect of smoking on no-reflow phenomenon is less investigated. The aim of this study was to compare no-reflow phenomenon after percutneous coronary intervention for acute myocardial infarction, between smokers and non smokers.

Materials And Methods: A total of 141 patients who were admitted to Chamran Hospital (Isfahan, Iran) between March and September, 2012 with a diagnosis of STEMI, enrolled into our Cohort study. Patients were divided into current smoker and nonsmoker groups (based on patient's information). All patients underwent primary PCI or rescue PCI within the first 12-h of chest pain. No-reflow phenomenon, thrombolysis in myocardial infarction (MI) flow, and 24-h complications were assessed in both groups.

Results: A total of 47 current smoker cases (32.9%) and 94 (65.7%) nonsmoker cases were evaluated. Smokers in comparison to nonsmokers were younger (53.47 ± 10.59 vs. 61.46 ± 10.55, P < 0.001) and they were less likely to be hypertensive (15.2% vs. 44.7%, P < 0.001), diabetic (17% vs. 36.2%, P < 0.05), and female gender (4.3% vs. 25.5%, P < 0.01). Angiographic and procedural characteristics of both groups were similar. 9 patients died during the first 24-h after PCI (4.3% of smokers and 6.4% of nonsmokers, P: 0.72). No-reflow phenomenon was observed in 29.8% of current smokers and 31.5% of nonsmokers (P = 0.77).

Conclusion: No-reflow phenomenon or short-term complications were not significantly different between current smokers and non smokers.

Citing Articles

Case Report: Smoking as the risk factor of persistent STEMI after primary percutaneous coronary intervention: how it could be happen?.

Pintaningrum Y, Yusuf R, Ramdani B, Putri S, Wulandari D F1000Res. 2024; 11:801.

PMID: 39493285 PMC: 11528186. DOI: 10.12688/f1000research.109757.3.

Clinical, Laboratory, and Procedural Predictors of No-Reflow in Patients Undergoing Primary Percutaneous Coronary Intervention.

Shakiba M, Salari A, Mirbolouk F, Sotudeh N, Nikfarjam S J Tehran Heart Cent. 2021; 15(2):50-56.

PMID: 33552194 PMC: 7825467. DOI: 10.18502/jthc.v15i2.4183.

Efficacy of combined endurance-resistance training versus endurance training in patients with heart failure after percutaneous coronary intervention: A randomized controlled trial.

Abolahrari-Shirazi S, Kojuri J, Bagheri Z, Rojhani-Shirazi Z J Res Med Sci. 2018; 23:12.

PMID: 29531564 PMC: 5842444. DOI: 10.4103/jrms.JRMS_743_17.

Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts.

Hashemi-Jazi M, Hosseini S, Gholamrezaei A ARYA Atheroscler. 2018; 13(5):221-229.

PMID: 29371868 PMC: 5774794.

References

Gao R . Current status and perspective of percutaneous coronary intervention in China. Chin Med J (Engl). 2006; 119(7):531-2. View

Hong Y, Jeong M, Choi Y, Ko J, Lee M, Kang W . Impact of plaque components on no-reflow phenomenon after stent deployment in patients with acute coronary syndrome: a virtual histology-intravascular ultrasound analysis. Eur Heart J. 2009; 32(16):2059-66. PMC: 3155758. DOI: 10.1093/eurheartj/ehp034. View

Rezkalla S, Dharmashankar K, Abdalrahman I, Kloner R . No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interv Cardiol. 2010; 23(5):429-36. DOI: 10.1111/j.1540-8183.2010.00561.x. View

Kirma C, Izgi A, Dundar C, Tanalp A, Oduncu V, Aung S . Clinical and procedural predictors of no-reflow phenomenon after primary percutaneous coronary interventions: experience at a single center. Circ J. 2008; 72(5):716-21. DOI: 10.1253/circj.72.716. View

Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne R . 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010; 55(21):2383-9. DOI: 10.1016/j.jacc.2009.12.054. View

Sukiennik A, Kozinski M, Debska-Kozinska K, Kubica A, Grabczewska Z, Kubica J . Smokers versus non-smokers undergoing percutaneous transluminal coronary angioplasty: The impact of clinical and procedural characteristics on in-hospital mortality. Cardiol J. 2008; 14(5):482-92. View

Teo K, Ounpuu S, Hawken S, Pandey M, Valentin V, Hunt D . Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet. 2006; 368(9536):647-58. DOI: 10.1016/S0140-6736(06)69249-0. View

Iwakura K, Ito H, Kawano S, Shintani Y, Yamamoto K, Kato A . Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol. 2001; 38(2):472-7. DOI: 10.1016/s0735-1097(01)01405-x. View

Jeong Y, Kim W, Park D, Choi B, Lee S, Kim Y . Serum B-type natriuretic peptide on admission can predict the 'no-reflow' phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial infarction. Int J Cardiol. 2009; 141(2):175-81. DOI: 10.1016/j.ijcard.2008.11.189. View

10.

Higashikuni Y, Tanabe K, Tanimoto S, Aoki J, Yamamoto H, Nakazawa G . Impact of culprit plaque composition on the no-reflow phenomenon in patients with acute coronary syndrome: an intravascular ultrasound radiofrequency analysis. Circ J. 2008; 72(8):1235-41. DOI: 10.1253/circj.72.1235. View

11.

Jesel L, Morel O, Ohlmann P, Germain P, Faure A, Jahn C . Role of pre-infarction angina and inflammatory status in the extent of microvascular obstruction detected by MRI in myocardial infarction patients treated by PCI. Int J Cardiol. 2007; 121(2):139-47. DOI: 10.1016/j.ijcard.2006.10.022. View

12.

Weisz G, Cox D, Garcia E, Tcheng J, Griffin J, Guagliumi G . Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. Am Heart J. 2005; 150(2):358-64. DOI: 10.1016/j.ahj.2004.01.032. View

13.

Albertal M, Cura F, Escudero A, Thierer J, Trivi M, Padilla L . Mechanism involved in the paradoxical effects of active smoking following primary angioplasty: a subanalysis of the protection of distal embolization in high-risk patients with acute myocardial infarction trial. J Cardiovasc Med (Hagerstown). 2008; 9(8):810-2. DOI: 10.2459/JCM.0b013e3282f73519. View

14.

Sorajja P, Gersh B, Costantini C, McLaughlin M, Zimetbaum P, Cox D . Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. Eur Heart J. 2005; 26(7):667-74. DOI: 10.1093/eurheartj/ehi167. View

15.

Niccoli G, Giubilato S, Russo E, Spaziani C, Leo A, Porto I . Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur Heart J. 2008; 29(15):1843-50. DOI: 10.1093/eurheartj/ehn325. View

16.

Chen Z, Boreham J . Smoking and cardiovascular disease. Semin Vasc Med. 2005; 2(3):243-52. DOI: 10.1055/s-2002-35392. View

17.

Thygesen K, Alpert J, Jaffe A, Simoons M, Chaitman B, White H . Third universal definition of myocardial infarction. Glob Heart. 2015; 7(4):275-95. DOI: 10.1016/j.gheart.2012.08.001. View

18.

Ndrepepa G, Tiroch K, Keta D, Fusaro M, Seyfarth M, Pache J . Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv. 2010; 3(1):27-33. DOI: 10.1161/CIRCINTERVENTIONS.109.896225. View

19.

Eitel I, Nowak M, Stehl C, Adams V, Fuernau G, Hildebrand L . Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging. Am Heart J. 2010; 159(5):882-90. DOI: 10.1016/j.ahj.2010.02.019. View

20.

Taggart D, Boyle R, de Belder M, Fox K . The 2010 ESC/EACTS guidelines on myocardial revascularisation. Heart. 2010; 97(6):445-6. DOI: 10.1136/hrt.2010.216135. View